Tirzepatide 20mg
£57.99
Dual GIP/GLP-1 receptor agonist — 20mg lyophilised research compound. Lab-verified, 99%+ purity.
In-Depth Research Guide
Mechanism of action, studies & citations
For professional laboratory research only.
- • Not a medicine.
- • Not sterile unless independently validated as sterile.
- • Not for administration to humans or animals.
- • Not for diagnostic or therapeutic use.
Live — What Others Are Viewing
Updates live
BPC-157 30mg
£67.99
Retatrutide 30mg
£87.99
Semaglutide 30mg
£59.99
GHK-Cu 100mg
£49.99
Follistatin 344 10mg
Coming Soon!
CJC-1295 (DAC) 10mg
Coming Soon!
Follistatin 315 10mg
Coming Soon!
Kisspeptin-54 10mg
Coming Soon!
Kisspeptin-10 10mg
Coming Soon!
CJC-1295 (No DAC) 10mg
Coming Soon!
Related Research Guides
In-depth research articles covering this compound and its laboratory applications.
The Complete Guide to Peptide Storage and Handling for Laboratory Research
Read guide
GLP-1 Receptor Agonist Comparison: Semaglutide vs Tirzepatide vs Retatrutide
Read guide
UK Peptide Research: A Landmark Guide to Research Communities Across Britain
Read guideUnderstanding Tirzepatide 20mg
A quick research-focused overview of this compound and what it's studied for.
What is it good for?
Dual increin (GIP + GLP-1) receptor signalling models in in-vitro and preclinical research.
What does it do?
A dual GIP/GLP-1 receptor agonist activating both major increin pathways, producing broader downstream metabolic research than a single-receptor compound.
Observed in research
In research models, dual agonism correlates with amplified insulin-sensitivity and energy-balance signalling effects versus GLP-1 alone.
For laboratory research use only. The effects described refer to observations in research models, not human use.
Customer Reviews
Log in to leave a review. Only verified customers can review our products.